This study aims to evaluate patients undergoing coronary angiography by comparing the use of Potassium Ferrate Hemostatic Sealant (PFHS) in addition to the standard of care (SOC) pneumatic radial compression device versus SOC alone. The objective is to determine whether the addition of PFHS reduces the time to successful deflation and removal of the radial compression device.
Trans radial access is commonly used for coronary angiography and Percutaneous Coronary Intervention (PCI) because it lowers bleeding risk and allows faster recovery compared with femoral access. However, achieving safe hemostasis while keeping the radial artery open is important, as prolonged or excessive compression can lead to radial artery occlusion. At MAHI, hemostasis is currently managed with a pneumatic compression device and a 60-90 minute compression period before deflation. Reducing the time to safe device deflation and removal could improve patient comfort, reduce nursing workload, and support earlier discharge. This is particularly important in a centralized healthcare system like Alberta's, where many patients travel long distances for care and may benefit from shorter and more predictable recovery times.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
300
PFHS applied at arteriotomy + pneumatic radial compression device placement; deflation protocol starts at 20 minutes using the Stat Seal 2-step deflation method regardless of PCI procedure.
Pneumatic radial compression device alone (no PFHS) + identical deflation protocol starts at 60 minutes for diagnostic procedures and 90 minutes for PCI procedures
PFHS plus pneumatic radial compression
PFHS plus pneumatic radial compression initiated at 20 minutes, compared with pneumatic radial compression alone.
Time frame: Immediately after the intervention
Time to patient discharge between trial arms
Time to patient discharge between trial arms.
Time frame: Immediately after the intervention
Radial artery patency at discharge compared between both trial arms
Plethysmography and pulse oximetry with reverse Barbeau testing (A-D classification).
Time frame: Immediately after the intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.